AtriCure Company Profile (NASDAQ:ATRC)

Analyst Ratings

Consensus Ratings for AtriCure (NASDAQ:ATRC) (?)
Ratings Breakdown: 8 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.14 (70.81% upside)

Analysts' Ratings History for AtriCure (NASDAQ:ATRC)
Show:
DateFirmActionRatingPrice TargetActions
7/12/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016JMP SecuritiesInitiated CoverageOutperform$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Needham & Company LLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Northland SecuritiesInitiated CoverageOutperform$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016BTIG ResearchReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Piper Jaffray Cos.Reiterated RatingOutperform$25.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2015Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2015Stifel NicolausBoost Price TargetBuy$25.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2015Dougherty & CoBoost Price TargetBuy$25.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for AtriCure (NASDAQ:ATRC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q116($0.32)($0.31)$36.08 million$35.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415($0.36)($0.36)$35.90 million$35.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015Q315($0.22)($0.22)$31.32 million$31.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2015Q215($0.21)($0.18)$30.51 million$32.58 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2015Q115($0.21)($0.19)$28.65 million$29.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2015Q414($0.20)($0.20)$28.40 million$29.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314($0.17)($0.02)$25.60 million$26.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2014Q214($0.19)($0.10)$25.03 million$26.51 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2014Q114($0.22)($0.31)$23.36 million$24.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.14)($0.24)$21.16 million$21.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313($0.15)($0.13)$18.30 million$20.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013($0.10)($0.09)$19.42 million$20.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013($0.09)($0.10)$18.63 million$19.43 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2013Q4 2012($0.09)($0.12)$18.46 million$18.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312($0.11)($0.16)$17.29 million$16.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.07)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2012($0.13)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2011($0.07)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2011($0.01)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AtriCure (NASDAQ:ATRC)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.33)($0.27)($0.30)
Q2 20162($0.31)($0.29)($0.30)
Q3 20162($0.32)($0.30)($0.31)
Q4 20162($0.34)($0.28)($0.31)
Q1 20171($0.25)($0.25)($0.25)
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AtriCure (NASDAQ:ATRC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AtriCure (NASDAQ:ATRC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/8/2016Elizabeth D KrellDirectorSell10,000$16.91$169,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Douglas J. SeithCOOSell5,000$21.55$107,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2015Elizabeth D. KrellDirectorSell10,000$21.88$218,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Elizabeth D. KrellDirectorSell10,000$20.68$206,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Michael D HoovenDirectorSell142,268$20.81$2,960,597.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2015Michael D HoovenDirectorSell20,000$20.51$410,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Michael D HoovenDirectorSell85,000$21.01$1,785,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Karen P RobardsDirectorSell3,150$19.53$61,519.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Douglas J SeithCOOSell36,688$17.51$642,406.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Elizabeth D KrellDirectorSell10,000$17.63$176,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014Douglas SeithSVPBuy1,000$15.04$15,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Richard JohnstonInsiderSell77,610$10.00$776,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Douglas SeithSVPBuy10,000$9.58$95,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2013Richard JohnstonInsiderSell20,047$10.00$200,470.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2013Richard M JohnstonInsiderSell2,343$10.00$23,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013Richard M JohnstonInsiderSell29,348$8.96$262,958.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2013Richard M JohnstonInsiderSell39,682$9.18$364,280.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Richard M JohnstonInsiderSell95,598$8.97$857,514.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Richard M JohnstonInsiderSell35,372$9.01$318,701.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2013James L LuckyVPSell50,065$8.14$407,529.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2012Mark R LanningDirectorBuy11,006$7.64$84,085.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2012Michael D HoovenDirectorBuy1,110$7.37$8,180.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2012Michael D HoovenDirectorBuy1,150$7.10$8,165.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2012Michael D HoovenDirectorBuy1,145$7.18$8,221.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2012Michael D HoovenDirectorBuy1,215$7.15$8,687.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/7/2012Michael D HoovenDirectorBuy1,215$6.88$8,359.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/23/2012Karen P RobardsDirectorBuy1,000$6.70$6,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2012Karen P RobardsDirectorBuy1,000$6.98$6,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AtriCure (NASDAQ:ATRC)
DateHeadline
07/22/16 05:08 PMAtriCure to Present at the Canaccord Genuity Growth Conference - [at noodls] - MASON, Ohio--(BUSINESS WIRE)--Jul. 22, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that ...
07/19/16 08:49 AMBioSig Technologies Issues Shareholder Letter
07/11/16 03:23 PMAtriCure to Announce Second Quarter 2016 Financial Results - [at noodls] - MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial ...
07/07/16 07:09 AMAtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : July 7, 2016 -
07/01/16 10:40 AMAtriCure : Receives CE Mark for the AtriClip® PRO2 Device
06/29/16 07:21 AMAtriCure Receives CE Mark for the AtriClip® PRO2 Device - [at noodls] - CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio--(BUSINESS ...
06/22/16 02:39 PMAtriCure : Announces the First Patient Enrolled in the FROST Cryoanalgesia Study
06/21/16 07:00 AMAtriCure Announces the First Patient Enrolled in the FROST Cryoanalgesia Study - [Business Wire] - AtriCure, Inc. , a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, MI.
06/20/16 07:15 AMAtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : June 20, 2016 -
06/17/16 12:16 PMBRIEF-AtriCure files for mixed shelf offering of up to $150 mln - * Atricure Inc files for secondary stock shelf offering of up to $115.2 million
06/15/16 05:25 AMSeveral Ohio companies named to ‘Most Trustworthy’ list -
06/09/16 12:39 PMAtriCure, Inc. – Value Analysis (NASDAQ:ATRC) : June 9, 2016 -
06/08/16 07:10 AMAtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : June 8, 2016 -
05/27/16 01:34 PMATRICURE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secu -
05/26/16 08:50 AMEarnings Review and Stock Rundown for AtriCure, Inc. (NASDAQ:ATRC) - Wall Street Hints and News - Earnings Review and Stock Rundown for AtriCure, Inc. (NASDAQ:ATRC)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting AtriCure, Inc. (NASDAQ:ATRC) to post ...and more »
05/24/16 05:37 PMAtriCure, Inc. (NASDAQ:ATRC) Impact Score At 50 - Investor Newswire - AtriCure, Inc. (NASDAQ:ATRC) Impact Score At 50Investor NewswireAlpha One explored various online articles released on AtriCure, Inc. (NASDAQ:ATRC), and it set a daily sentiment score of -0.355 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content ...and more »
05/22/16 10:06 PMAfter Last Week What Do Analysts Think Of AtriCure, Inc. (ATRC) - Share Trading News - After Last Week What Do Analysts Think Of AtriCure, Inc. (ATRC)Share Trading News02/28/2014 – AtriCure, Inc. had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 33 price target on the stock. The share price of AtriCure, Inc. (ATRC) was up +0.93% during the last trading session, with a ...
05/13/16 10:57 PMAtriCure Inc. (ATRC) Hits New 52-week Low During May 12 Session - Equities.com - AtriCure Inc. (ATRC) Hits New 52-week Low During May 12 SessionEquities.comAtriCure Inc. (ATRC) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $14.20, AtriCure Inc. dropped to $13.44 for a new 52-week low. By the closing bell, the company's stock was at $13.78 a share ...
05/10/16 05:48 PMConsensus Rating Review for AtriCure, Inc. (NASDAQ:ATRC) - B.O.D.Y Confidential - Consensus Rating Review for AtriCure, Inc. (NASDAQ:ATRC)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of AtriCure, Inc. (NASDAQ:ATRC). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or Hold ...and more »
05/06/16 05:47 PMAtriCure Becomes Oversold (ATRC) - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of AtriCure Inc (ATRC) entered into oversold territory, hitting an RSI reading of 28.8, after changing hands as low as $13.89 per share. By comparison ...
05/06/16 12:04 PMATRICURE, INC. Financials -
05/05/16 11:16 PMAtriCure Inc. (ATRC) Hits New 52-week Low During May 04 Session - Equities.com - AtriCure Inc. (ATRC) Hits New 52-week Low During May 04 SessionEquities.comAtriCure Inc. (ATRC) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $14.50, AtriCure Inc. dropped to $14.23 for a new 52-week low. By the closing bell, the company's stock was at $14.38 a share ...and more »
05/04/16 10:55 PMAtriCure Inc. (ATRC) Hits New 52-week Low During May 03 Session - Equities.com - AtriCure Inc. (ATRC) Hits New 52-week Low During May 03 SessionEquities.comAtriCure Inc. (ATRC) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $14.57, AtriCure Inc. dropped to $14.50 for a new 52-week low. By the closing bell, the company's stock was at $14.51 a share ...and more »
05/04/16 12:24 PMAtriCure, Inc. :ATRC-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/03/16 11:02 PMAtriCure Inc. (ATRC) is Trading Lower on Unusual Volume for May 02 - Equities.com - AtriCure Inc. (ATRC) is Trading Lower on Unusual Volume for May 02Equities.comAtriCure Inc. (ATRC) experienced unusually high volume on May. 02, as the stock lost 6.29% to a closing price of $14.90. The stock saw 527,605 shares trade hands over the course of the day on 4,216 trades. Given that the stock's average daily volume ...
05/03/16 11:02 PMAtriCure Inc. (ATRC) Hits New 52-week Low During May 02 Session - Equities.com - AtriCure Inc. (ATRC) Hits New 52-week Low During May 02 SessionEquities.comAtriCure Inc. (ATRC) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $15.96, AtriCure Inc. dropped to $14.59 for a new 52-week low. By the closing bell, the company's stock was at $14.90 a share ...and more »
05/03/16 05:50 PMAverage Analyst Rating for AtriCure, Inc. (NASDAQ:ATRC) - B.O.D.Y Confidential - Average Analyst Rating for AtriCure, Inc. (NASDAQ:ATRC)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on AtriCure, Inc. (NASDAQ:ATRC) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/03/16 05:50 PMAtriCure Inc. (ATRC) Drops 6.29% on May 02 - Equities.com - AtriCure Inc. (ATRC) Drops 6.29% on May 02Equities.comAtriCure Inc. (ATRC) was one of the Russell 2000's biggest losers for Monday May 02 as the stock slid 6.29% to $14.90, a loss of $-1 per share. Starting at an opening price of $15.96 a share, the stock traded between $14.59 and $16.16 over the course ...and more »
05/03/16 12:36 PMETF’s with exposure to AtriCure, Inc. : May 3, 2016 -
05/03/16 11:10 AMAtriCure Suffers From Weak Chart, Downgrade -
05/02/16 06:08 PMStock Runners: AtriCure, Inc. (NASDAQ:ATRC), Perrigo Company plc Ordinary Shares (NYSE:PRGO), Mitsubishi UFJ ... - KC Register - Stock Runners: AtriCure, Inc. (NASDAQ:ATRC), Perrigo Company plc Ordinary Shares (NYSE:PRGO), Mitsubishi UFJ ...KC RegisterAtriCure, Inc. (NASDAQ:ATRC) announced that it has entered into an amended and restated term loan and revolving line of credit agreement with Silicon Valley Bank, providing access to a new $25 million five-year term loan, as well as renewing a $15 ...and more »
05/02/16 03:20 PMAtriCure to Present at the UBS Global Healthcare Conference - [at noodls] - MASON, Ohio--(BUSINESS WIRE)--May 2, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it ...
05/02/16 07:14 AMAtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : May 2, 2016 -
04/29/16 05:54 PMShare Performance and Target Price Review AtriCure, Inc. (NASDAQ:ATRC) - B.O.D.Y Confidential - Share Performance and Target Price Review AtriCure, Inc. (NASDAQ:ATRC)B.O.D.Y ConfidentialDuring the most recent trading session, shares of AtriCure, Inc. (NASDAQ:ATRC) ended up with a move of -6.53%. Sell-side analysts have given a consensus target price of $24.63 on company shares. Target price projections may differ greatly from one ...and more »
04/29/16 02:33 PMEdited Transcript of ATRC earnings conference call or presentation 28-Apr-16 8:30pm GMT -
04/29/16 10:43 AMATRICURE, INC. Files SEC form 10-Q, Quarterly Report -
04/28/16 06:11 PMPeek Under The Hood: XHE Has 10% Upside - ... XHE's underlying holdings with notable upside to their analyst target prices are Heartware International Inc (HTWR), AtriCure Inc (ATRC), and Cerus Corp. (CERS). Although HTWR has traded at a recent price of $34.30/share, the average analyst target is ...
04/28/16 04:41 PMAtriCure reports 1Q loss -
04/28/16 03:36 PMAtriCure Reports First Quarter 2016 Financial Results - [at noodls] - Revenue of $35.9 million - up 20.3% as reported, 20.4% constant currency U.S. sales of $28.3 million - up 23.3% International sales of $7.7 million - up 10.1% as reported, 10.9% constant currency MASON, ...
04/28/16 03:36 PMAtriCure Announces $25 Million Term Loan with Silicon Valley Bank - [at noodls] - MASON, Ohio--(BUSINESS WIRE)--Apr. 28, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that ...
04/28/16 03:30 PMAtriCure Inc Earnings Call scheduled for 4:30 pm ET today -
04/28/16 03:22 PMATRICURE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financial Co -
04/28/16 03:02 PM4:02 pm AtriCure amended and restated term loan and revolving line of credit agreement; provides access to a new $25 mln five-year term loan as well as renewing a $15 mln revolving line of credit -
04/28/16 06:07 AMQ1 2016 AtriCure Inc Earnings Release - After Market Close -
04/28/16 04:23 AMLatest Analyst Ratings For AtriCure, Inc. (ATRC) - Share Trading News - Latest Analyst Ratings For AtriCure, Inc. (ATRC)Share Trading NewsAtriCure, Inc. has a 50 day moving average of 16.79 and a 200 day moving average of 18.74. The stock's market capitalization is 543.75M, it has a 52-week low of 14.85 and a 52-week high of 28.15. The share price of the company (ATRC) was up +1.49%, ...Are Analysts Bearish AtriCure Inc. (NASDAQ:ATRC) After Last Week?Franklin IndependentAtriCure, Inc. (NASDAQ:ATRC) Wall Street Rating in FocusNews Tribuneall 4 news articles »
04/27/16 06:01 PMAtriCure, Inc. (NASDAQ:ATRC) Wall Street Rating in Focus - News Tribune - AtriCure, Inc. (NASDAQ:ATRC) Wall Street Rating in FocusNews TribuneZacks.com, founded by Len Zacks, a Mathematics Ph.D. from M.I.T. who discovered that earnings estimate revisions are the most powerful force impacting stock prices, track 6 equity research firms that cover shares of AtriCure, Inc. (NASDAQ:ATRC). Sell ...and more »
04/27/16 04:47 AMAtriCure receives FDA clearance for its AtriClip PRO2 Left Atrial Appendage Exclusion System - MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip ...
04/26/16 06:10 PMFDA clears AtriCure's new LAA exclusion device - Seeking Alpha - FDA clears AtriCure's new LAA exclusion deviceSeeking AlphaAtriCure (NASDAQ:ATRC) receives 510(k) clearance for its AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System for use in minimally-invasive surgical procedures. The new device features increased functionality including an ambidextrous locking ...AtriCure Receives FDA Clearance for New AtriClip® DeviceBusiness Wire (press release)all 2 news articles »
04/26/16 06:10 PMAtriCure, Inc. (NASDAQ:ATRC) Share Rating Recap - B.O.D.Y Confidential - AtriCure, Inc. (NASDAQ:ATRC) Share Rating RecapB.O.D.Y ConfidentialShares of AtriCure, Inc. (NASDAQ:ATRC) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...
04/26/16 06:10 PMAtriCure Inc. (ATRC) is Trading Higher on Unusual Volume for April 25 - Equities.com - AtriCure Inc. (ATRC) is Trading Higher on Unusual Volume for April 25Equities.comAtriCure Inc. (ATRC) experienced unusually high volume on Apr. 25, as the stock gained 2.05% to a closing price of $16.94. The stock saw 445,643 shares trade hands over the course of the day on 3,694 trades. Given that the stock's average daily volume ...and more »

Social

About AtriCure

AtriCure logoAtriCure, Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company's segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. Its Isolator Synergy System, which includes its Isolator Synergy clamps, radio frequency (RF) generator and related switchbox, provides treatment for persistent and long-standing persistent Afib concomitant. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Equipment
  • Exchange: NASDAQ
  • Symbol: ATRC
  • CUSIP: 04963C20
Key Metrics:
  • Previous Close: $14.72
  • 50 Day Moving Average: $15.02
  • 200 Day Moving Average: $16.06
  • P/E Ratio: N/A
  • P/E Growth: -0.64
  • Market Cap: $487.14M
  • Beta: 0.91
  • Current Year EPS Consensus Estimate: $-1.19 EPS
  • Next Year EPS Consensus Estimate: $-0.94 EPS
Additional Links:
AtriCure (NASDAQ:ATRC) Chart for Friday, July, 29, 2016